meta_pixel
Tapesearch Logo
Log in
The Excerpt

The blockbuster cancer drug Keytruda can cost over $150,000

The Excerpt

USA TODAY

News, Daily News

4.11.2K Ratings

🗓️ 15 April 2026

⏱️ 13 minutes

🧾️ Download transcript

Summary

Last December, President Donald Trump convened a meeting of pharmaceutical executives with the goal of getting them to lower the cost of prescription drugs. A few weeks later, one patient battling lung cancer checked into a California clinic for an infusion of Merck & Co.'s blockbuster cancer drug, Keytruda. When the bill arrived, the clinic's charge for a 400 mg dose dominated the page: It was just over $162,000. While Brown only owed about $2,000 herself, the six-figure charges show how quickly prices for cutting-edge medical treatments can balloon in the U.S. health care system. USA TODAY joined the International Consortium of Investigative Journalists in their year-long, reporting effort looking into rising healthcare costs around the world. USA TODAY Health Reporter Ken Alltucker joined The Excerpt to share his insights.

Let us know what you think of this episode by sending an email to podcasts@usatoday.com

Episode transcript available here

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Transcript

Click on a timestamp to play from that location

0:00.0

In the race to scale with AI, you need data infrastructure that can match your pace.

0:05.0

Everpure's data storage platform brings all your data into one hub.

0:08.8

No silos, no scrambling, just instant access to tame your data chaos.

0:13.5

And with Everpure storage as a service subscription, your storage and security upgrade automatically with zero downtime,

0:20.0

your infrastructure stays current, so your

0:21.9

business never slows down. Visit everpuredata.com to learn more today. With Everpure, you're

0:27.3

not just in the race. You're built to win it. Last December, President Donald Trump

0:36.7

convened a meeting of pharmaceutical executives with a goal of convincing them to lower the cost of prescription drugs.

0:43.8

As of today, 14 out of the 17 largest pharmaceutical companies, but they've all agreed, have now agreed to drastically lower drug prices for their American patients, for the American people and patients.

0:57.7

A few weeks later, Patricia Brown, Cook, battling lung cancer, checked into a California clinic

1:03.3

for an infusion of Mergen Co's blockbuster cancer drug, Ketruda.

1:08.3

When the bill arrived, the clinic's charge for a 400 milligram dose dominated the page.

1:13.6

It was just over $162,000. Hello and welcome to USA Today's The Excerpt. I'm Dana Taylor.

1:21.2

Today is Wednesday, April 15, 26. While Brown only owed about $2,000 herself, the six-figure charges to Brown and her insurance company show how quickly prices for cutting-edge medical treatments can balloon in the U.S. health care system.

1:37.3

USA Today joined the International Consortium of Investigative Journalists in their year-long reporting effort looking into rising health care costs around the world.

1:46.5

Joining me to share what this investigation has revealed is USA Today Health Reporter, Ken Oltucker.

1:52.2

It's good to have you back, Ken.

1:53.6

Thank you for having me.

1:55.0

Ken, let's start with some basics here.

1:57.5

What kind of cancer is Ketruda used to treat and how much does say a year's worth of

2:03.9

drug cost? Ketruda is an immunotherapy and it's approved for several different types of cancer. Some

2:12.2

common types of cancer include melanoma and advanced breast cancer. And it's really became sort of the

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from USA TODAY, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of USA TODAY and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.